Pacira Pharmaceuticals (PCRX) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($4.96 million) and the uptick to downtick ratio was 0.75. The transaction value on upticks was $14.61 million and on downticks, the transaction value was $19.57 million. In block trades, the transaction value of inflow done during uptick was $1.44 million. The transaction value of block trades during downticks was $3.81 million. The uptick to downtick block trade ratio was 0.38. The money flow was negative ($2.37 million), indicating the traders were booking profit on the price strength. Pacira Pharmaceuticals (PCRX) rose $2.63 at $38.32, during intraday Wednesday , a rise of 7.37% over the previous days close.
Also, In a research note released to the investors, Brean Capital downgrades its rating on Pacira Pharmaceuticals (NASDAQ:PCRX).The analysts at the brokerage house have a current rating of Hold on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on July 1, 2016.
Pacira Pharmaceuticals (NASDAQ:PCRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.82 and $35.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $39.74. The buying momentum continued till the end and the stock did not give up its gains. It closed at $38.53, notching a gain of 7.96% for the day. The total traded volume was 1,731,096 . The stock had closed at $35.69 on the previous day.
The stock has recorded a 20-day Moving Average of 5.49% and the 50-Day Moving Average is 6.9%. In a related news, The director, of Pacira Pharmaceuticals, Inc., Brege Laura had unloaded 1,000 shares at $46.95 per share in a transaction on June 6, 2016. The total value of transaction was $46,950. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.